Explore Tonix Pharmaceuticals Holding's Fair Values from the Community and select yours

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So, the natural question for Tonix Pharmaceuticals Holding (NASDAQ:TNXP) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

Does Tonix Pharmaceuticals Holding Have A Long Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In June 2025, Tonix Pharmaceuticals Holding had US$125m in cash, and was debt-free. In the last year, its cash burn was US$65m. That means it had a cash runway of around 23 months as of June 2025. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time.

How Well Is Tonix Pharmaceuticals Holding Growing?

On balance, we think it's mildly positive that Tonix Pharmaceuticals Holding trimmed its cash burn by 13% over the last twelve months. But the revenue dip of 21% in the same period was a bit concerning. Considering both these factors, we're not particularly excited by its growth profile. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Tonix Pharmaceuticals Holding To Raise More Cash For Growth?

Even though it seems like Tonix Pharmaceuticals Holding is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Tonix Pharmaceuticals Holding's cash burn of US$65m is about 13% of its US$523m market capitalisation. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted.

So, Should We Worry About Tonix Pharmaceuticals Holding's Cash Burn?

On this analysis of Tonix Pharmaceuticals Holding's cash burn, we think its cash runway was reassuring, while its falling revenue has us a bit worried. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about Tonix Pharmaceuticals Holding's situation. On another note, Tonix Pharmaceuticals Holding has 3 warning signs (and 2 which shouldn't be ignored) we think you should know about.

Of course Tonix Pharmaceuticals Holding may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.